Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

New antibiotic launched for C diff


The first in a new class of antibiotics was launched in the UK last week for the treatment of Clostridium difficile infection.

Fidaxomicin (Dificlir) is manufactured by Astellas Pharma. In a statement announcing the drug’s launch, the company said fidaxomicin demonstrated a similar efficacy and safety profile to vancomycin in trials.

But fidaxomicin more than halved the rate of infection recurrence compared to vancomycin, 12.7% versus 26.9%.


Readers' comments (3)

  • hope it has a better effect on patients with c diff,and help them have a speed recovery....

    Unsuitable or offensive? Report this comment

  • yes but dose it have the same side affects as vancomycin

    Unsuitable or offensive? Report this comment

  • how long would it take for resistance to build up?

    Unsuitable or offensive? Report this comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.